Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer

Value in Health

Volumn 16, Issue 2, 2013, Pages 288-296

  Hoyle, Martin ^a   Peters, Jaime ^a   Crathorne, Louise ^a   Jones Hughes, Tracey ^a   Cooper, Chris ^a   Napier, Mark ^b   Hyde, Chris ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

cetuximab; colorectal cancer; cost effectiveness; cost utility; decision analytic modeling; Erbitux; irinotecan; panitumumab; Vectibix

Indexed keywords

CETUXIMAB; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG COST; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT DURATION; UNITED KINGDOM; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, NEOPLASM; GREAT BRITAIN; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; STATE MEDICINE; SURVIVAL ANALYSIS;

EID: 84875447994     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.11.001     Document Type: Article

References (27)

1. Cancer Research UK. CancerStats key facts: large bowel cancer (colorectal cancer). 2011. Available from: http://info.cancerresearchuk.org/prod-consump/ groups/cr-common/@nre/@sta/documents/generalcontent/crukmig-1000ast-2806.pdf. [Accessed December 18, 2012]
2. Aravani A., Thomas J., Day M., et al. Survival by stage of colorectal cancer in England. Northern and Yorkshire Cancer Registry and Information Service. Available from: http://www.nycris.nhs.uk/uploads/doc/vid-6573- Colorectal%20survval%20by%20stage-%20A.Aravani3%20rtg%202c.pdf, 2009. [Accessed November 16, 2012].
3. A. Grothey, D. Sargent, and R.M. Goldberg Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209 1214
4. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
5. N. Mittmann, H.J. Au, and D. Tu Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial J Natl Cancer Inst 101 2009 1182 1192
6. P.R. Blank, H. Moch, and T.D. Szucs KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective Clin Cancer Res 17 2011 6338 6346
7. National Institute of Health and Clinical Excellence. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy. NICE technology appraisal guidance 242. Available from: http://www.nice.org.uk/nicemedia/live/13651/57924/57924.pdf, 2012. [Accessed November 16, 2012].
8. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
9. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
10. M. Hoyle, G. Rogers, and T. Moxham Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia Value Health 14 2011 1057 1067
11. National Institute of Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London, UK 2008.
12. Hoyle M, Crathorne L, Peters J, et al. The effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with (non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model. 2011. Available from: http://guidance.nice.org.uk/TA/WaveR/102/Consultation/EvaluationReport/ AssessmentReport/pdf/English. [Accessed November 16, 2012].
13. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
14. W. De Roock, H. Piessevaux, and J. De Schutter KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 2008 508 515
15. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
16. A. Lievre, J.B. Bachet, and V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379
17. H.C. Bucher, G.H. Guyatt, and L.E. Griffith The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
18. P. Kind, G. Hardman, and S.U.K. Macran Population Norms for EQ-5D 1999 Centre for Health Economics discussion paper series 172 York, UK
19. N. Starling, D. Tilden, and J. White Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment Br J Cancer 96 2007 206 212
20. B.M.J. Group British National Formulary (BNF) 63 2012 BMJ Group and RPS Publishing London
21. J.J. Sacco, and J. Botten Macbeth F, et al. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study PLoS One 5 2010 e8933
22. Cardiff & Vale NHS Trust. KRAS & Tumour Mutation Testing. Available from: http://www.wales.nhs.uk/sites3/page.cfm?orgid=525&pid=34097. [Accessed November 16, 2012].
23. Department of Health. NHS Reference Costs 2008-2009. Available from: http://www.dh.gov.uk/. 2008-2009. [Accessed November 16, 2012].
24. Curtis L. Unit costs of health and social care. 2010. Available from: http://www.pssru.ac.uk/uc/uc2011contents.htm. [Accessed April 4, 2011].
25. E. Remak, and L. Brazil Cost of managing women presenting with stage IV breast cancer in the United Kingdom Br J Cancer 91 2004 77 83
26. J. Tol, J.R. Dijkstra, and M.E. Vink-Borger High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue J Cell Mol Med 14 2010 2122 2131
27. M. Drummond, M. Barbieri, and J. Cook Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report Value Health 12 2009 409 418